{"id":63,"date":"2017-06-29T11:40:51","date_gmt":"2017-06-29T09:40:51","guid":{"rendered":"https:\/\/www.degro.org\/ag-stereotaxie\/?page_id=63"},"modified":"2023-07-19T17:39:43","modified_gmt":"2023-07-19T15:39:43","slug":"sbrt-for-primary-liver-cancer","status":"publish","type":"page","link":"https:\/\/www.degro.org\/ag-stereotaxie\/projekte\/abgeschlossene-projekte\/sbrt-for-primary-liver-cancer\/","title":{"rendered":"HepReg Trial"},"content":{"rendered":"<div id=\"pl-63\"><style scoped>#pg-63-0 .panel-grid-cell { float:none } #pl-63 .panel-grid-cell .so-panel { margin-bottom:30px } #pl-63 .panel-grid-cell .so-panel:last-child { margin-bottom:0px } #pg-63-0 { margin-left:-15px;margin-right:-15px } #pg-63-0 .panel-grid-cell { padding-left:15px;padding-right:15px } #panel-63-0-0-0 a { color:#009cd8 } @media (max-width:780px){ #pg-63-0 .panel-grid-cell { float:none;width:auto } #pl-63 .panel-grid , #pl-63 .panel-grid-cell {  } #pl-63 .panel-grid .panel-grid-cell-empty { display:none } #pl-63 .panel-grid .panel-grid-cell-mobile-last { margin-bottom:0px }  } <\/style><div class=\"panel-grid\" id=\"pg-63-0\" ><div class=\"panel-grid-cell\" id=\"pgc-63-0-0\" ><div class=\"so-panel widget widget_sow-editor panel-first-child panel-last-child\" id=\"panel-63-0-0-0\" data-index=\"0\"><div class=\"so-widget-sow-editor so-widget-sow-editor-base\">\n<div class=\"siteorigin-widget-tinymce textwidget\">\n\t<h2><strong>Stereotactic body radiotherapy (SBRT) for primary liver tumors (HepReg)<\/strong><\/h2>\n<hr \/>\n<h4><strong>Study PI:<\/strong><\/h4>\n<p>Prof. Dr. med. Thomas Brunner<br \/>\nUniversity Hospital Graz<br \/>\n<a href=\"mailto:thomas.brunner@medunigraz.at\">thomas.brunner@medunigraz.at<\/a><\/p>\n<p>PD Dr. med. Danny Jazmati<br \/>\nUniversity Hospital D\u00fcsseldorf<br \/>\n<a href=\"mailto:danny.jazmati@med.uni-duesseldorf.de\">danny.jazmati@med.uni-duesseldorf.de<\/a><\/p>\n<h4>Status:<\/h4>\n<p>Recruiting centers ( Contact Danny Jazmati for participation)<\/p>\n<h4><strong>Study design: <\/strong><\/h4>\n<p>\u25cf Multi-center, international retrospective and prospective study<\/p>\n<h4><strong>Study objective:<\/strong><\/h4>\n<ul>\n<li>To perform a patterns-of-care and patterns-of-outcome analysis of SBRT for primary liver tumors in Germany, Austria and Switzerland<\/li>\n<li>To evaluate patient and treatment factor influencing outcome in SBRT for primary liver tumors<\/li>\n<\/ul>\n<h4><strong>Project status:<\/strong><\/h4>\n<ul>\n<li>First Round Data collection completed<\/li>\n<li>3 full manuscripts published<\/li>\n<li>Second Round analysis planned<\/li>\n<\/ul>\n<h3><strong>Major findings and results:<br \/>\n<\/strong><\/h3>\n<p>Bettinger D, Pinato DJ, Schultheiss M, et al (2019) <strong>Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis.<\/strong> Liver Cancer 8:281\u2013294.<br \/>\n<a href=\"http:\/\/www.pubmed.ncbi.nlm.nih.gov\/31602371\/\" target=\"_blank\" rel=\"noopener\">www.pubmed.ncbi.nlm.nih.gov\/31602371\/<\/a><\/p>\n<ul>\n<li>International retrospective matched pair analysis of patients with advanced hepatocellular carcinoma treated with SBRT or sorafenib<\/li>\n<li>122 patients treated with SBRT and 901 patients treated with sorafenib were compared for overall survival and progression-free survival<\/li>\n<li>Baseline characteristics between groups were adjusted by propensity score matching<\/li>\n<li>Median overall survival in adjusted, matched analysis:<br \/>\n16.0 months SBRT group vs. 9.6 months sorafenib group (HR 0.53, p=0.005)<\/li>\n<li>Progression-free survival in adjusted, matched analysis:<br \/>\n9.0 months SBRT group vs. 6.0 months sorafenib group (HR 0.59, p=0.004)<\/li>\n<\/ul>\n<p>Brunner TB, Blanck O, Lewitzki V, et al (2019) <strong>Stereotactic body radiotherapy dose and its impact on local control and overall survival of patients for locally advanced intrahepatic and extrahepatic cholangiocarcinoma.<\/strong> Radiotherapy and Oncology 132:42\u201347.<br \/>\n<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/30825968\/\" target=\"_blank\" rel=\"noopener\">www.pubmed.ncbi.nlm.nih.gov\/30825968\/<\/a><\/p>\n<ul>\n<li>64 patients with 82 non-resectable primary lesions of cholangiocarcinomas treated with SBRT were analyzed retrospectively for overall survival, local control, and toxicity<\/li>\n<li>Median follow-up 35 months, median OS 15 months, 2-y-OS 32%, 3-y-OS 21%<\/li>\n<li>Stat. significant prognostic factor for LC and OS in univariate analysis: biologically effective dose (BEDmax&gt;91 Gy10)<\/li>\n<li>BEDmax&gt;91 Gy10: 1-y-LC 91%, 2-y-LC 80%, median OS 24 months<\/li>\n<li>BEDmax&lt;91 Gy10: 1-y-LC 66%, 2-y-LC 39%, median OS 13 months<\/li>\n<li>Tumor size and PTV were neither predictive nor prognostic for LC or OS<\/li>\n<li>Toxicity: 17% G1 gastroduodenitis, 11% G2-3 cholangitis, 4.7% G3 GI-bleeding<\/li>\n<\/ul>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>#pg-63-0 .panel-grid-cell { float:none } #pl-63 .panel-grid-cell .so-panel { margin-bottom:30px } #pl-63 .panel-grid-cell .so-panel:last-child { margin-bottom:0px } #pg-63-0 { margin-left:-15px;margin-right:-15px } #pg-63-0 .panel-grid-cell { padding-left:15px;padding-right:15px } #panel-63-0-0-0 a { color:#009cd8 } @media (max-width:780px){ #pg-63-0 .panel-grid-cell { float:none;width:auto } #pl-63 .panel-grid <\/p>\n","protected":false},"author":8,"featured_media":0,"parent":758,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/www.degro.org\/ag-stereotaxie\/wp-json\/wp\/v2\/pages\/63"}],"collection":[{"href":"https:\/\/www.degro.org\/ag-stereotaxie\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.degro.org\/ag-stereotaxie\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.degro.org\/ag-stereotaxie\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/www.degro.org\/ag-stereotaxie\/wp-json\/wp\/v2\/comments?post=63"}],"version-history":[{"count":14,"href":"https:\/\/www.degro.org\/ag-stereotaxie\/wp-json\/wp\/v2\/pages\/63\/revisions"}],"predecessor-version":[{"id":965,"href":"https:\/\/www.degro.org\/ag-stereotaxie\/wp-json\/wp\/v2\/pages\/63\/revisions\/965"}],"up":[{"embeddable":true,"href":"https:\/\/www.degro.org\/ag-stereotaxie\/wp-json\/wp\/v2\/pages\/758"}],"wp:attachment":[{"href":"https:\/\/www.degro.org\/ag-stereotaxie\/wp-json\/wp\/v2\/media?parent=63"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}